SCHEMBL18667291

SCHEMBL18667291

C=C[S+]([O-])N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 20/20 0.72
▸ EGFR P00533 3/20 0.72
▸ TEC P42680 3/20 0.72
▸ BMX P51813 3/20 0.72
▸ LYN P07948 3/20 0.72
▸ TXK P42681 2/20 0.72
▸ FGFR2 P21802 2/20 0.72
▸ ITK Q08881 2/20 0.72
▸ LCK P06239 2/20 0.72
▸ BLK P51451 2/20 0.72
▸ RIPK2 O43353 1/20 0.72
▸ NR1I2 O75469 1/20 0.72
▸ SLC22A3 O75751 1/20 0.72
▸ LATS1 O95835 1/20 0.72
▸ NUDT14 O95848 1/20 0.72
▸ ABL1 P00519 1/20 0.72
▸ ERBB2 P04626 1/20 0.72
▸ FYN P06241 1/20 0.72
▸ PGR P06401 1/20 0.72
▸ CSF1R P07333 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189862 1.00 BTK (0.72) BTKEGFRTECBMXLYN
SCHEMBL19649201 0.88 BTK (0.70) BTKEGFRTECBMXLYN
SCHEMBL4910818 0.88 BTK (0.79) BTKEGFRTECBMXLYN
SCHEMBL2730415 0.87 BTK (0.69) BTKEGFRTECBMXLYN
SCHEMBL16075646 0.85 BTK (0.77) BTKEGFRTECBMXLYN
SCHEMBL21897775 0.84 BTK (0.74) BTKEGFRTECBMXLYN
SCHEMBL21897777 0.84 BTK (0.74) BTKEGFRTECBMXLYN
Ibrutinib SCHEMBL201859 0.84 BTK (1.00) BTKEGFRTECBMXLYN
Ibrutinib SCHEMBL2244865 0.84 BTK (1.00) BTKEGFRTECBMXLYN
Ibrutinib SCHEMBL201641 0.84 BTK (1.00) BTKEGFRTECBMXLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017046746-A1 THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR AND A GITR BINDING MOLECULE, A 4-1BB AGONIST, OR AN OX40 AGONIST ACERTA PHARMA B.V. (NL) 2017-03-23 — — WO disclosed
Send feedback